By Karen Roman Private equity company Jeito Capital said it is co-leading an oversubscribed €77.7 million (USD 84.8 million) ...
Jeito Capital said it invested in Callio Therapeutics’ $187M Series A round to support its next-generation multi-payload antibody-drug conjugates (ADCs) for cancer treatment. Callio Therapeutics ...
The German firm licensed a PRMT5 inhibitor that’s now in Phase 1 testing. Elsewhere, GSK is testing an intriguing hypothesis ...
Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round Novo Holdings and Jeito Capital co-led the ...
Hosted on MSN27d
Callio raises $187m for proof-of-concept for dual-payload ADCFrazier Life Sciences led the financing round with substantial contributions from Jeito Capital and other investors including Omega Funds, Novo Holdings, ClavystBio and Pureos Bioventures.
It has turned to its existing investors to fund the latest round, which was led by Jeito Capital and UPMC Enterprises, with backing from 4BIO Capital, Ysios Capital, Bpifrance, and Foundation ...
Jeito Capital co-leads the oversubscribed €78 million financing in Augustine Therapeutics to develop novel therapies for neuromuscular, cardio-metabolic and neurodegenerative diseases Proceeds ...
Novo Holdings and Jeito Capital co-led the deal, supported by Asabys Partners and existing investors Proceeds to support the clinical development of lead candidate AGT-100216 for the treatment of ...
Novo Holdings and Jeito Capital co-led the deal, supported by Asabys Partners and existing investors Proceeds to support the clinical development of lead candidate AGT-100216 for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback